Tempus AI Raises 2025 Financial Outlook: What's Backing It?
Robust First-Quarter Performance: Total sales in the first quarter amounted to $255.7 million, which grew 75.4% year over year. Quarterly gross profit increased 99.8% year over year, reaching $155.2 million. The gains were fueled by lab efficiencies, increased adoption of AI tools like Tempus One and xM and a higher mix of data services. These improvements narrowed down adjusted EBITDA loss to $16.2 million, from $43.9 million a year ago.
Strategic Collaborations With AstraZeneca & Pathos: Tempus signed a three-year, $200 million data and modeling license agreement with AstraZeneca (AZN) and Pathos to build a multimodal foundation model in oncology, leveraging more than 300 petabytes of rich multimodal healthcare data that Tempus has built over the past decade. Notably, the deal raised the total remaining contract value to greater than $1 billion as of April-end.
Upside in Hereditary Testing: Hereditary testing revenues hit $63.5 million on 23% volume growth, outpacing the first-quarter guidance. This growth was driven by the acquisition of Ambry Genetics, a recognized leader in genetic testing. The company anticipates long-term potential in this business beyond oncology, extending to cardiovascular, Alzheimer's and other genetic predispositions.
For full-year 2025, Exact Sciences EXAS anticipates total revenues in the range of $3.070-$3.120 billion (previously $3.025-$3.085 billion). The adjusted EBITDA forecast is updated to the $425-$455 million band (up from the earlier range of $410-$440 million). A major catalyst for the guidance hike was the successful launch of Cologuard Plus, the company's next-generation colorectal cancer screening test. The test has already seen rapid adoption, with over 30,000 completed tests. TEM reported first-quarter revenues of $706.8 million, marking a 10.9% year-over-year increase. Adjusted EBITDA surged 61%, while free cash flow reached breakeven, an improvement of $120 million from the prior year. These results gave management the confidence to raise its full-year outlook.
Exelixis EXEL raised its full-year 2025 financial guidance following strong first-quarter results, driven by higher demand for CABOMETYX and the recent U.S. FDA approval for its use in treating advanced neuroendocrine tumors (NET). The company expects total revenues in the range of $2.25-$2.35 billion (up from the earlier guidance range of $2.15-$2.25 billion). A major factor behind this upward revision was the FDA approval in March 2025 of CABOMETYX for the treatment of advanced pancreatic and extra-pancreatic NET, making it the first and only systemic treatment approved for previously treated NET regardless of tumor site or grade. Additionally, TEM is optimistic about several upcoming clinical milestones in the second half of the year, including pivotal trial readouts for its next-generation therapy zanzalintinib in colorectal and non-clear cell renal cancers. These developments reinforce Exelixis' strategy to expand its oncology portfolio and transition into a multi-franchise cancer company.
In the past year, Tempus AI shares have surged 58.6%, outperforming the industry's 16.8% growth and the S&P 500 composite's 11% improvement.
Image Source: Zacks Investment Research
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 7.09X compared to the industry average of 5.82X.
Image Source: Zacks Investment Research
Earnings estimates for Tempus AI in 2025 and 2026 are showing a mixed picture.
Image Source: Zacks Investment Research
TEM stock currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Exelixis, Inc. (EXEL) : Free Stock Analysis Report
Exact Sciences Corporation (EXAS) : Free Stock Analysis Report
Tempus AI, Inc. (TEM) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time Magazine
9 hours ago
- Time Magazine
Should You Take a Vitamin B12 Supplement?
Everyone needs vitamin B12: It helps the body produce red blood cells and maintain healthy brain function, along with so many other things. But are you getting enough of it? Here's what to know about vitamin B12 and whether you should consider upping your levels. A boon for brain health 'Vitamin B12 is important for brain health because it helps protect nerve cells in the brain, which support memory and thinking skills,' says Michelle Routhenstein, a preventive cardiology dietitian and certified diabetes educator in New York. It's water-soluble, so the body does not store it in large amounts, and daily intake is essential. The current federal recommendations are for adults to get 2.4 mcg of vitamin B12 per day. Great food sources of B12 include seafood like oysters, salmon and tuna, beef, and fortified products like nutritional yeast, plant-based milks, some breads and breakfast cereals, says Routhenstein. But some recent research suggests that some people may need even more than that. Vitamin B12 deficiencies can impact your brain function even when your intake levels are considered normal, says Dr. Ari J. Green, a professor at the University of California, San Francisco's department of ophthalmology. In a recent study, Green and his colleagues found that people with B12 levels that were technically normal but on the lower end of the range had impaired brain function. 'We could detect neurological impairment at levels currently considered 'normal,' independently of other factors like years of education," particularly in older people, says Dr. Alexandra Beaudry-Richard, a resident at McGill University and co-author of the study. 'To us, this should reinvigorate a conversation about how much B12 is needed for optimal neurological function.' Read More: Should You Take a Vitamin D Supplement? Other studies have found that people with Alzheimer's disease and mild cognitive impairment tend to have lower B12 levels—and supplementation with B12 can reduce the rate of brain atrophy. However, on the opposite end, the study showed signs of a possible detrimental effect on the brain when people had high B12 levels in their blood. 'This warrants further studies to evaluate what healthy B12 levels are on both ends of the spectrum,' says Dr. Ahmed Abdelhak, one of the study's authors and a clinical instructor in neurology at UCSF School of Medicine. Should you take a B12 supplement? You can (and should) get B12 from your diet, but some people may have a tough time getting adequate levels of the nutrient from food alone. Older adults are more likely to develop vitamin B12 deficiencies because the vitamin requires stomach acid to be absorbed, and stomach acid production starts to decline with age. Routhenstein recommends people look closer into their B12 status starting around age 50 or if they are at higher risk of a B12 deficiency. This category includes vegans and vegetarians, people taking specific medications that interfere with B12 absorption such as metformin or proton pump inhibitors, and those who have gastrointestinal disorders like Crohn's, celiac, or atrophic gastritis. You can get tested for a vitamin B12 deficiency at your annual physical. If you are deficient, your doctor might recommend supplementation. Read More: 7 Surprising Symptoms of Lyme Disease The UCSF study authors recommend checking levels starting at age 70, but you can get it checked on a standard blood test at any age through your primary care physician. Dr. Ralph Green, a professor of pathology and lab medicine at the University of California, Davis—and another author on that recent study—says that checking B12 may also be valuable for people who have unexplained symptoms that have been linked to B12 deficiency. For those with declining gastric function, he says taking supplements is likely the best way to promote absorption, and the level of supplementation a person should consume depends on whether their absorption is normal or not. Pregnant women, too, need higher B12 intake to support fetal brain development; if you're pregnant, consult with your ob-gyn about optimal B12 levels for you. What kind of B12 supplement is best? B12 in supplements and fortified foods can be more easily absorbed than from food, especially for older adults and those with absorption issues, says Routhenstein. If your doctor has advised you to take a B12 supplement, it's best to ask them to recommend specific dosages and brands. But Routhenstein recommends following these general guidelines when selecting a B12 supplement. Of course, no supplement is a cure-all, and there are other ways to support brain health, including maintaining a healthy diet and exercise regimen. Activities that stimulate multiple brain areas simultaneously are excellent at promoting cognitive longevity, Beaudry-Richard says. Practicing a musical instrument, dancing, and studying a foreign language daily, for example, all recruit 'brain circuits responsible for vision, hearing, movement, emotions' and more. 'It's like a full-body workout for the brain,' she says.
Yahoo
a day ago
- Yahoo
IQVIA Holdings (IQV) Enters Partnership With Kexing Biopharm To Enhance Drug Development
IQVIA Holdings recently forged a strategic partnership with Kexing Biopharm, aiming to bolster the clinical development and market integration of innovative therapeutics globally. Over the last quarter, IQVIA's stock price rose by 19.52%, aligning closely with broader market trends. This partnership has likely contributed positively by highlighting the company's commitment to international expansion. Concurrently, the broader market optimism driven by expectations of potential Federal Reserve rate cuts added general upward momentum. Additionally, IQVIA's ongoing share buyback and continued focus on enhancing operational efficiencies might have further supported investor confidence during this period. We've discovered 1 warning sign for IQVIA Holdings that you should be aware of before investing here. The end of cancer? These 26 emerging AI stocks are developing tech that will allow early identification of life changing diseases like cancer and Alzheimer's. The recent strategic partnership between IQVIA Holdings and Kexing Biopharm could significantly enhance IQVIA's international reach, potentially fueling further revenue growth. This aligns with IQVIA's ongoing efforts to strengthen their market differentiation through AI and data analytics. Over a five-year period, IQVIA's total return was 11.51%, highlighting a moderate level of long-term appreciation. However, its one-year performance saw the company match the broader US Life Sciences industry's decline at 23.1%, indicating challenges in recent market conditions. The collaboration with Kexing Biopharm could also positively influence IQVIA's earnings forecasts, particularly as demand for real-world evidence and clinical research grows. This move may bolster their revenue streams as the company aims to maintain its competitive edge. The current share price of US$180.09 remains below the consensus analyst price target of US$213.05, indicating a potential upside if the company's strategic initiatives translate into anticipated financial performance. Understand IQVIA Holdings' earnings outlook by examining our growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include IQV. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Sign in to access your portfolio
Fox News
2 days ago
- Fox News
Study reveals why ‘super agers' maintain ‘outstanding memory' into their 80s
Many assume that memory loss and cognitive decline are an inevitable part of aging — but new research suggests that doesn't have to be the case. A 25-year study from Northwestern University analyzed the brains of "super agers" to determine what traits they share that may contribute to their mental resilience. "Super agers" are defined as people 80 and older who show "outstanding memory performance" that is on par with those who are three decades younger, according to the researchers. "'Super ager' is not a condition, but rather a term we defined at Northwestern on the basis of a score on a memory test over age 80," lead author Sandra Weintraub, a professor of psychiatry and behavioral sciences and neurology at the Northwestern University Feinberg School of Medicine, told Fox News Digital. "We were interested in memory aging because memory decline is the most common complaint in older adults. One can be 'super' in many ways, and this is just one." In the study, the researchers analyzed 79 brains that were donated by super agers and identified some key differences compared to those who "age typically." Some of the brains contained amyloid and tau proteins, which typically accumulate in people with Alzheimer's disease, while other brains showed no sign of these toxins. "Some super agers have very few of these proteins, so for some reason they don't manufacture them," Weintraub noted. "But we found some super agers' brains contained large numbers of these proteins, despite maintaining their cognitive health until death." This means there may be different biological pathways to super aging — "one resistance and the other resilience," she said. "If your relative is forgetful at age 80, it may not be part of aging, but of disease." With the resistance group, they don't make the plaques and tangles, Weintraub said. In the resilience group, they make them, but they don't have any impact on their brains. While "typically aging" brains show thinning of the cortex — which is the outer layer of the brain that helps with decision-making, motivation and regulation of emotions — the super agers' brains did not show this characteristic. Super agers were also found to have a greater number of "von economo neurons," which are brain cells that control social behavior. The researchers also found that this group had larger "entorhinal neurons," which are essential for powering memory, the release stated. In terms of behavior, the super agers were also found to be "highly social" with strong interpersonal relationships, according to the study findings. "There is the common assumption that aging implicitly brings cognitive decline and that loss of short-term memory is part of 'normal aging,'" lead author Sandra Weintraub, professor of psychiatry and neurology at Northwestern Medicine, told Fox News Digital. "The truth is that on average, cognitive test scores decline, but the variance among individuals within that average span gets larger and larger with age," she continued. "That means that loss is not inevitable, and that if your relative is forgetful at age 80, it may not be part of aging, but of disease." Christopher Weber, Ph.D., senior director of global science initiatives at the Alzheimer's Association in Chicago, was not involved in the study but commented on the "exciting" findings. "This increases our understanding of people's brains as they age and gives some insight into what makes some resilient or resistant to age-related brain changes," Weber told Fox News Digital. The study shows that super agers have "more preserved brain structure" that is similar to much younger adults, according to Weber. "The findings suggest that cognitive decline is not an inevitable part of aging — especially for individuals who have more protective factors that preserve brain health and cognition," he said. Weber pointed out, however, that the "super aging" study population is small and not representative of the real-world population. "They are primarily well-educated and White," he said. "Also, this group was self-selected into the study. These individuals may be more health-conscious or cognitively engaged than average older adults." Even so, the findings could help scientists create more — and better — strategies for treating and preventing cognitive decline, according to Weber. "The more we know about successful aging, the more opportunities we have to discover and create interventions to enhance resistance and resilience." To help reduce the risk factors that affect brain health, Weintraub said, "What is good for your heart is good for your brain." "What is good for your heart is good for your brain." "We know that adopting certain lifestyle changes will reduce the risk of a bad outcome, but are not guaranteed to eradicate it," she told Fox News Digital. "Having said that, eat well, sleep well, exercise, socialize and value social relationships, treat whatever condition you have that you can treat, and stay away from harmful substances." For more health articles, visit The study was supported by the Northwestern Alzheimer's Disease Research Center and the National Institute on Aging of the National Institutes of Health. The findings were published in Alzheimer's & Dementia: The Journal of the Alzheimer's Association.
